Relevant Pipeline Brings Gilead Closer to Direct Indian Presence
This article was originally published in PharmAsia News
Executive Summary
Long after it has established business links with Indian drug makers, Gilead Sciences is looking to set up its own India office. All these years, the US firm has stopped shy of a direct presence but the growing relevance of its drug pipeline to the local population now makes this a strategic imperative, say industry insiders.
You may also be interested in...
Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development
Gilead Fights For Viread Patent And Royalties In India
Gilead Sciences is challenging a decision in India refusing patent protection for its worldwide HIV blockbuster drug Viread (tenofovir)
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.